Adamas Pharmaceuticals reported -12573000 in Net Income for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Abbvie ABBV:US $ 766M 2787M
Acadia Pharmaceuticals ACAD:US $ -43.87M 22.58M
Aerie Pharmaceuticals AERI:US $ -38.69M 3.28M
Aptinyx Inc APTX:US $ -19819000 5.59M
Biocryst Pharmaceuticals BCRX:US $ -43.2M 21.09M
Flexion Therapeutics FLXN:US $ -22208000 6.35M
GlaxoSmithKline GSK:LN 1395M 322M
Glaxosmithkline GSK:US $ 1395M 322M
Gw Pharmaceuticals GWPH:US $ -19.68M 9.47M
Heron Therapeutics HRTX:US $ -61.02M 8.4M
Intra Cellular Therapies ITCI:US $ -68.74M 16M
Marinus Pharmaceuticals MRNS:US $ -23.82M 3.32M
Merk MRK:US $ 1545M 1634M
Neurocrine Biosciences NBIX:US $ 42.3M 10.2M
Novartis NOVN:VX SF 2896M 837M
Omeros OMER:US $ -28593000 6.5M
Prothena PRTA:US $ 27.64M 64.38M
Revance Therapeutics RVNC:US $ -72.2M 0.56M
Teva Pharmaceutical TEVA:IT 207M 129M
Zogenix ZGNX:US $ -58.9M 3.27M